NCT04358406 - Rhu-pGSN for Severe Covid-19 Pneumonia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 30, 2020

Primary Completion Date

May 25, 2021

Study Completion Date

January 28, 2022

Conditions

Sars-CoV2

Interventions

DRUG

Recombinant human plasma gelsolin (Rhu-pGSN)

Intravenous administration of rhu-pGSN at 12 mg/kg, 3 doses

OTHER

Placebo

Normal saline in matched volume to treatment arm. Undistinguishable in syringe.

Trial Locations (3)

Spitalul Clinic de Boli Infecţioase şi Pneumoftiziologie, Timișoara

Sant Joan de Reus SAM University Hospital, Reus

Hospital Universitari de Tarragona Joan XXIII, Tarragona